UBS Group’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-321
| Closed | -$1.05K | – | 11549 |
|
|
2022
Q4 | $1.05K | Hold |
321
| – | – | ﹤0.01% | 9976 |
|
|
2022
Q3 | $1K | Sell |
321
-679
| -68% | -$2.32K | ﹤0.01% | 10249 |
|
|
2022
Q2 | $3K | Buy |
1,000
+892
| +826% | +$4.13K | ﹤0.01% | 9485 |
|
|
2022
Q1 | $1K | Sell |
108
-1,485
| -93% | -$15.2K | ﹤0.01% | 10131 |
|
|
2021
Q4 | $22K | Buy |
1,593
+1,485
| +1,375% | +$37.3K | ﹤0.01% | 7764 |
|
|
2021
Q3 | $5K | Sell |
108
-50
| -32% | -$2.16K | ﹤0.01% | 8602 |
|
|
2021
Q2 | $7K | Sell |
158
-437
| -73% | -$19.2K | ﹤0.01% | 8396 |
|
|
2021
Q1 | $29K | Buy |
595
+234
| +65% | +$13.6K | ﹤0.01% | 7054 |
|
|
2020
Q4 | $36K | Buy |
361
+179
| +98% | +$15.7K | ﹤0.01% | 6491 |
|
|
2020
Q3 | $12K | Sell |
182
-1,117
| -86% | -$97.5K | ﹤0.01% | 6729 |
|
|
2020
Q2 | $137K | Sell |
1,299
-449
| -26% | -$53.3K | ﹤0.01% | 5078 |
|
|
2020
Q1 | $155K | Sell |
1,748
-1,360
| -44% | -$162K | ﹤0.01% | 4922 |
|
|
2019
Q4 | $355K | Buy |
3,108
+1,198
| +63% | +$90.1K | ﹤0.01% | 5147 |
|
|
2019
Q3 | $118K | Buy |
1,910
+1,190
| +165% | +$95.3K | ﹤0.01% | 5669 |
|
|
2019
Q2 | $56K | Buy |
720
+448
| +165% | +$50.8K | ﹤0.01% | 5824 |
|
|
2019
Q1 | $36K | Sell |
272
-680
| -71% | -$71.4K | ﹤0.01% | 5795 |
|
|
2018
Q4 | $76K | Buy |
+952
| New | +$93.9K | ﹤0.01% | 5776 |
|
|
2018
Q3 | – | Sell |
-37
| Closed | -$4K | – | 8396 |
|
|
2018
Q2 | $4K | Buy |
+37
| New | +$4.19K | ﹤0.01% | 7584 |
|
|
2018
Q1 | – | Sell |
-53
| Closed | -$9K | – | 8311 |
|
|
2017
Q4 | $9K | Sell |
53
-1,998
| -97% | -$512K | ﹤0.01% | 7116 |
|
|
2017
Q3 | $646K | Buy |
2,051
+772
| +60% | +$244K | ﹤0.01% | 4028 |
|
|
2017
Q2 | $380K | Buy |
1,279
+1,259
| +6,295% | +$337K | ﹤0.01% | 4320 |
|
|
2017
Q1 | $5K | Buy |
+20
| New | +$3.46K | ﹤0.01% | 7014 |
|
|
2016
Q3 | – | Sell |
-160
| Closed | -$12K | – | 8053 |
|
|
2016
Q2 | $12K | Buy |
+160
| New | +$16K | ﹤0.01% | 6692 |
|
|
2016
Q1 | – | Sell |
-121
| Closed | -$19K | – | 8378 |
|
|
2015
Q4 | $19K | Buy |
+121
| New | +$18.1K | ﹤0.01% | 6820 |
|
|
2015
Q1 | – | Sell |
-83
| Closed | -$34K | – | 9581 |
|
|
2014
Q4 | $34K | Buy |
+83
| New | +$21.7K | ﹤0.01% | 6977 |
|
Other funds holding CALA
UBS Group's CALA Position: Q1 2023 in Review
UBS Group sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 321 shares — an estimated $1.05K sold.
UBS Group first reported a position in CALA in Q4 2014 and held it in 25 quarters. The position peaked at $646K in Q3 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- UBS Group reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 321 Calithera Biosciences, Inc shares in Q1 2023, an estimated $1.05K.
- UBS Group first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 25 quarters.
- UBS Group's Calithera Biosciences, Inc position peaked at $646K in Q3 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.